{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T13:07:16Z","timestamp":1777468036619,"version":"3.51.4"},"reference-count":10,"publisher":"SAGE Publications","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["BD"],"published-print":{"date-parts":[[2023,12,5]]},"abstract":"<jats:p>BACKGROUND: Metastatic breast cancer (MBC) is incurable. Systemic therapy is the standard treatment; however, an optimal sequence of chemotherapy has not been established. OBJECTIVE: Evaluating effectiveness and safety of eribulin in MBC treatment and comparing the results obtained with published literature. METHODS: Observational, descriptive and retrospective study of patients with MBC treated with eribulin from 01\/12\/2015 to 30\/10\/2021. Effectiveness was analysed using Kaplan\u2013Meier-survival-curves, for the overall number of patients treated and stratified by treatment line. Safety was measured according to adverse events (AE) based on CTCAE v5.0. Data analysis was performed using R v4.0.1. RESULTS: They were included in this study 53 women who received eribulin (median age 58 years). Comparison of median survival from this study versus published data were: progression-free-survival (PFS) 3 (IC95%: 3\u20134) versus 3.7 months and overall-survival (OS) 8 (IC95%: 3\u20134) versus 13.2 months for the overall number of patients. For the 1\u20133 line treatment group, PFS was 6 (IC95%: 3-NA) and OS was 15 (IC95%: 6-NA). There were 322 AEs, the most frequent being blood disorders 16% (52), general disorders 12% (38), and gastrointestinal disorders 12% (38). CONCLUSIONS: The median PFS was similar to that reported previously, with lower OS. There was a tendency to achieve better results when eribulin was used earlier. Eribulin is a less well-tolerated drug than published literature.<\/jats:p>","DOI":"10.3233\/bd-230031","type":"journal-article","created":{"date-parts":[[2023,12,6]],"date-time":"2023-12-06T06:49:23Z","timestamp":1701845363000},"page":"349-360","source":"Crossref","is-referenced-by-count":1,"title":["Eribulin in metastatic breast cancer: Real world data"],"prefix":"10.1177","volume":"42","author":[{"given":"Clara Luz","family":"Fern\u00e1ndez-Laguna","sequence":"first","affiliation":[{"name":", Hospital Universitario Central de Asturias, , Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ivan","family":"Maray","sequence":"additional","affiliation":[{"name":", Hospital Universitario Central de Asturias, , Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lola","family":"Macia-Rivas","sequence":"additional","affiliation":[{"name":", Hospital Universitario Central de Asturias, , Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cristina","family":"\u00c1lvarez-Asteinza","sequence":"additional","affiliation":[{"name":", Hospital Universitario Central de Asturias, , Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sergio","family":"Fern\u00e1ndez-Lastras","sequence":"additional","affiliation":[{"name":", Hospital Universitario Central de Asturias, , Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Veronica","family":"Velasco Dur\u00e1ntez","sequence":"additional","affiliation":[{"name":", Hospital Universitario de Cabue\u00f1es, , Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M\u00f3nica","family":"Carbajales \u00c1lvarez","sequence":"additional","affiliation":[{"name":", Hospital Universitario Central de Asturias, , Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana","family":"Lozano-Bl\u00e1zquez","sequence":"additional","affiliation":[{"name":", Hospital Universitario Central de Asturias, , Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","reference":[{"issue":"2","key":"10.3233\/BD-230031_ref4","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1111\/his.14091","article-title":"The 2019 World Health Organization classification of tumours of the breast","volume":"77","author":"Tan","year":"2020","journal-title":"Histopathology [Internet]"},{"issue":"2","key":"10.3233\/BD-230031_ref5","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1159\/000350774","article-title":"A brief overview of the WHO classification of breast Tumors, 4th edition, focusing on issues and updates from the 3rd edition","volume":"8","author":"Sinn","year":"2013","journal-title":"Breast Care (Basel) [Internet]"},{"issue":"4","key":"10.3233\/BD-230031_ref6","doi-asserted-by":"publisher","first-page":"477","DOI":"10.4103\/ijpm.ijpm_201_18","article-title":"Evaluation of CD4+ T-cells and CD8+ T-cells in triple-negative invasive breast cancer","volume":"61","author":"Jagtap","year":"2018","journal-title":"Indian J Pathol Microbiol [Internet]"},{"issue":"35","key":"10.3233\/BD-230031_ref7","doi-asserted-by":"publisher","first-page":"3959","DOI":"10.1200\/jco.21.01392","article-title":"Endocrine treatment and targeted therapy for hormone receptor\u2013positive, human epidermal growth factor receptor 2\u2013negative metastatic breast cancer: ASCO guideline update","volume":"39","author":"Burstein","year":"2021","journal-title":"J Clin Oncol [Internet]"},{"issue":"12","key":"10.3233\/BD-230031_ref8","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.1016\/j.annonc.2021.09.019","article-title":"ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer","volume":"32","author":"Gennari","year":"2021","journal-title":"Ann Oncol [Internet]"},{"key":"10.3233\/BD-230031_ref9","unstructured":"Lurie RH, Anderson BO, Abraham J, Aft R, Agnese D, Allison KH , NCCN Clinical practice guidelines in oncology (NCCN Guidelines\u00ae), Breast Cancer Version 4.2023 [Internet]2023. Autumn. Available from: https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/breast.pdf."},{"issue":"9769","key":"10.3233\/BD-230031_ref12","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1016\/S0140-6736(11)60070-6","article-title":"Eribulin monotherapy versus treatment of physicians choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study","volume":"377","author":"Cortes","year":"2011","journal-title":"Lancet [Internet]"},{"issue":"6","key":"10.3233\/BD-230031_ref13","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1200\/jco.2013.52.4892","article-title":"Phase III open-label randomized study of eribulin mesylate versus capecitabine in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline and a taxane","volume":"33","author":"Kaufman","year":"2015","journal-title":"J Clin Oncol [Internet]"},{"issue":"103375","key":"10.3233\/BD-230031_ref14","doi-asserted-by":"publisher","first-page":"103375","DOI":"10.1016\/j.critrevonc.2021.103375","article-title":"Comparative effectiveness and safety of eribulin in advanced or metastatic breast cancer: a systematic review and meta-analysis","volume":"163","author":"Tanni","year":"2021","journal-title":"Crit Rev Oncol Hematol [Internet]"},{"key":"10.3233\/BD-230031_ref21","unstructured":"Maughan KL, Lutterbie MA, Ham PS, Treatment of breast cancer, Am Fam Physician [Internet], 81(11)2010. [cited 2023 Sep 10]. Available from: https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/20521754."}],"container-title":["Breast Disease"],"original-title":[],"link":[{"URL":"https:\/\/content.iospress.com\/download?id=10.3233\/BD-230031","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T13:32:38Z","timestamp":1777383158000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/full\/10.3233\/BD-230031"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,5]]},"references-count":10,"journal-issue":{"issue":"1"},"URL":"https:\/\/doi.org\/10.3233\/bd-230031","relation":{},"ISSN":["0888-6008","1558-1551"],"issn-type":[{"value":"0888-6008","type":"print"},{"value":"1558-1551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,5]]}}}